TRIPLE-NEGATIVE BREAST CANCER AND HR+/HER2- BC

Clinical trials for TRIPLE-NEGATIVE BREAST CANCER AND HR+/HER2- BC explained in plain language.

Never miss a new study

Get alerted when new TRIPLE-NEGATIVE BREAST CANCER AND HR+/HER2- BC trials appear

Sign up with your email to follow new studies for TRIPLE-NEGATIVE BREAST CANCER AND HR+/HER2- BC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New drug combo trial offers hope for Tough-to-Treat breast cancer

Disease control Ongoing

This study is testing two experimental drug combinations for people with advanced HER2-negative breast cancer that cannot be removed by surgery. Researchers want to see if adding a second drug (KL-A167) to the main treatment (SKB264) works better than using SKB264 alone. The tria…

Matched conditions: TRIPLE-NEGATIVE BREAST CANCER AND HR+/HER2- BC

Phase: PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control

Last updated Mar 30, 2026 14:31 UTC

TRIPLE-NEGATIVE BREAST CANCER AND HR+/HER2- BC

Get alerted when new TRIPLE-NEGATIVE BREAST CANCER AND HR+/HER2- BC trials appear

New drug combo trial offers hope for Tough-to-Treat breast cancer